Available Technologies
# of Displayed Technologies: 10 / 57
AI-Enabled Retrosynthesis for Drug Development
TS-060092 — AI methods and systems for predicting reactants and their synthesis paths to support drug design and chemical synthesis.
A time-consuming and costly step in drug development is the identification of drug-like small molecules that display desired properties against a specific biomolecular target and then the synthesis of such molecules if they do not exist. Retrosynthesis is a procedure where such a desired molecule i…
- College: College of Medicine (COM)
- Inventors: Ning, Xia; Chen, Ziqi
- Licensing Officer: Csatary, Erika
FraB as a drug target and FraB inhibitors as Salmonella-specific narrow-spectrum therapeutics
TS-059635 — & T2014-282 A method to discover narrow-spectrum antibiotics of salmonellosis, as well as small molecule inhibitors of Salmonella FraB and a Salmonella probiotic strain to enhance the efficacy of FraB inhibitors.
Non-typhoidal salmonellosis is one of the most significant food-borne diseases, in the United States and globally. There are no vaccines available for human use to prevent this disease, and only broad-spectrum antibiotics available to treat the disease. However, antibiotic resistance is on the ris…
- College: College of Medicine (COM)
- Inventors: Ahmer, Brian; Boulanger, Erin; Cool, Austin; Gopalan, Venkat; Kovvali, Sai Sravya Varali; Law, Jamison; Lindert, Steffen; Sabag-Daigle, Anice; Sengupta, Anindita; Thirugnanasambantham, Pankajavalli
- Licensing Officer: Csatary, Erika
Diagnostic for Early Detection of Heart Damage
TS-059578 — A novel biomarker for the early identification of cardiac damage, including chemotherapy-induced cardiotoxicity.
Despite significant medical advances and technologies, cardiovascular disease remains the number one cause of death in the United States, irrespective of gender or race, resulting in more than 600,000 annual deaths. Additionally, while cancer survivorship has increased significantly, the number one …
- College: College of Medicine (COM)
- Inventors: Smith, Sakima; Dib, Patrick; McElroy, Craig
- Licensing Officer: Csatary, Erika
Metabolite-Based Diagnostics for Joint Infection
TS-059537 — An untargeted NMR-based metabolomics approach to identify metabolic compounds as signatures of bacterial joint infections and methods for the treatment and prevention thereof.
Pseudomonas aeruginosa, a biofilm-producing pathogenic bacterium, exhibits resistance to many antibiotics. This leads to acute and chronic joint infections that are difficult to treat. Accordingly, a critical need exists for accurate biofilm diagnosis, prevention, and treatment. While culture-free…
- College: College of Medicine (COM)
- Inventors: Stoodley, Paul; Bruschweiler, Rafael; Leggett, Abigail
- Licensing Officer: Csatary, Erika
SimPi: A Remote Power Platform for Simulation
TS-059056 — A platform for improving simulations across many industries.
Developing real-life simulations of disasters is vital for safety and reducing their financial impact; however, current simulation tools are bulky, expensive to implement, and require advanced technical skills to operate.
Simulations are essential for evaluating the potential impacts of disasters and for creating effective preparedness and response plans to facilitate organized and coordinated actions. Since response plans are not theoretical exercises, they must frequently be tested to be evaluated, adapted, and u…
- College: College of Medicine (COM)
- Inventors: Winfield, Scott; Beck, James; Finnegan, Geoff
- Licensing Officer: Csatary, Erika
DAT-CI knock-in mouse model carrying a modified dopamine transporter that maintains the transport function but resistant to cocaine inhibition and thus showing no rewarding cocaine effects
TS-058669 — A knock-in mouse model carrying a modified dopamine transporter that is resistant to cocaine inhibition and thus showing no rewarding cocaine effects.
Cocaine abuse has been an issue in the United States since the late 1980s. The highly addictive qualities along with the low cost ruined people’s lives and destroyed communities. Naloxone (marketed as Narcan) is highly effective but can only be used in the event of an overdose. Therefore, th…
- College: College of Medicine (COM)
- Inventors: Gu, Howard
- Licensing Officer: Davis, Stewart
NET-CI knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that maintains the transport function and makes the transporter protein resistant to cocaine and antidepressants
TS-058668 — A knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that makes the transporter protein resistant to cocaine and antidepressants.
Cocaine abuse has been an issue in the United States since the late 1980s. Furthermore, antidepressants also quite dangerous, with nearly 14% of users (who have bipolar disorder) experiencing dependence. Naloxone (marketed as Narcan) is highly effective but can only be used in the event of an over…
- College: College of Medicine (COM)
- Inventors: Gu, Howard
- Licensing Officer: Davis, Stewart
Rabbit Model for Duchenne Muscular Dystrophy
TS-058084 — A rabbit model has been created for Duchenne Muscular Dystrophy (DMD) that more closely resembles the effects experienced in humans while being more cost effective compared to larger animal models.
There has yet to be a DMD animal model that bridges the gap between cost effectiveness and scientific relevance. This new rabbit model does that.
DMD is a lethal genetic disease characterized by progressive muscle weakness and muscle wasting. There are several animal models for DMD, includin…
- College: College of Medicine (COM)
- Inventors: Han, Renzhi
- Licensing Officer: Schworer, Adam
Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 —
A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
- College: College of Medicine (COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
- College: College of Medicine (COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
